From TokenPost · · 40s
Veradermics' VDPHL01 Meets All Endpoints
Veradermics' lead hair loss treatment meets all study endpoints in Phase 3 trial.
In brief
Veradermics' lead hair loss treatment meets all study endpoints in Phase 3 trial. Veradermics' VDPHL01 met all primary and secondary endpoints in the six-month Phase 3 study for mild-to-moderate pattern hair loss. Originally reported by TokenPost.
Study Results
Veradermics' lead candidate VDPHL01 met all primary and secondary endpoints in the six-month placebo-controlled Part A of Phase 3 Study '304' for men with mild-to-moderate pattern hair loss.
Trial Details
The six-month study enrolled 536 men with mild-to-moderate pattern hair loss, also known as androgenetic alopecia.
Significance
This positive late-stage result applies to the six-month comparison with placebo, not the study's longer extension phase.
The big picture
Veradermics' VDPHL01 met all primary and secondary endpoints in the six-month Phase 3 study for mild-to-moderate pattern hair loss.
